4 Deaths, 17 Injuries: Medtronic's Flagship Pipeline Vantage Embolization Device Recalled in Class I Action

Editor: Yu Bai

Today (March 19, 2025) morning, according to Reuters, Medtronic is conducting a campaign for its produced Pipeline Vantage embolization device.Initiate a recall action, recall levelDon't worry aboutThe most severe level, andInvolves withdrawal from sites currently in use or for sale, means a series of equipmentMay cause serious injury or death。

Image source: Reuters

The information disclosed on the FDA's official website shows that the flexible braided tube component of this product has a high probability of connection abnormality risk during use, specifically manifested asIncomplete apposition of vascular wallsAndDeformation of Woven Structure(Including complications such as fish-mouth deformation, narrowing of the lumen, or radial collapse).Among them, the risk for female patients is particularly significant, especially for women under the age of 45.

This defect may lead to serious clinical consequences, including but not limited to thromboembolism, ischemic stroke, and fatal complications.

According to the adverse event monitoring data,Model 027 Pipeline VantageThe embolization device has triggered13 serious injury incidents and 4 fatal cases；Products of the same type as Model 021This involves4 Cases of Injury Incidents。

The specific product information is as follows:

Medtronic advises customers not to use and to return all unused 027-type products, and to read the updated instructions before using the 021-type product.

For patients who have already been implanted with the affected devices, the attending physician should decide whether enhanced imaging follow-up or optimization of treatment management strategies is necessary based on the overall health assessment results.

Against the backdrop of an aging population, the prevalence of aneurysm diseases is also increasing year by year.

"Craniotomy for Aneurysm Clipping" and "Endovascular Coiling for Aneurysm Embolization" are the two traditional treatment methods for aneurysms. However,With the rapid development of neurointerventional materials and techniques, the treatment of cerebrovascular diseases has entered the era of minimally invasive interventions.A New Approach to Treating Aneurysms —— The Emergence of Flow Diverter Implantation。

According to Huang Xiaosong, Director of the Department of Neurology III at Hunan Provincial Second People's Hospital (Provincial Brain Hospital),The dense mesh stent is composed of dozens of visibleWoven from fine metal wires, the mesh is very tightly knit with extremely small pores, offering excellent flexibility. It adheres to the vessel wall of long aneurysms, making it difficult for blood flow to enter the aneurysm. It has a strong flow-diverting effect and can reduce the risk of intraoperative rupture and bleeding.

Mr. Xiao Kejin, Director of the Neurology Department of Yueyang Traditional Chinese Medicine Hospital, said that the blood flow导向密网支架 implantation surgery isThe Most Advanced Technology in the Field of Cerebrovascular Treatment Currently，Through the revolutionary "vascular reconstruction" concept, using high-density braided stents, the blood flow velocity within aneurysms decreases by more than 95%., fundamentally blocking the blood supply to the tumor and promoting natural repair of the vascular endothelium. The cure rate of this technology is 40% higher than traditional methods, with a recurrence rate reduced to less than 3%.

Medtronic's Recall This TimeThe Pipeline™ Embolization Device is a popular product in the field of flow diversion.Data shows that the productBased on 10 years of experience and extensive clinical research，Initially, it was in 2015.Acquired for $43 billion when purchasing Covidien，It has now been updated to the fourth generation.

First-generation PipelineA self-expanding cylinder woven from 36 cobalt-chromium wires and 12 platinum-tungsten wires in a 3:1 ratio.

The Second GenerationPipeline FlexWith an improved delivery microcatheter, the PED can be retracted and reopened for easier redeployment. It also replaces the retrieval string with a dual polytetrafluoroethylene sleeve to eliminate the challenge of stent opening. The product received FDA approval in 2015.

The Third Generation Pipeline Flex-ShieldApproved by the FDA in 2021, the product is made from 48 woven strands (including 36 cobalt-chromium wires and 12 platinum wires) to achieve radiopacity. Its surface is modified with a phosphorylcholine polymer to reduce the incidence of stent thrombosis and vascular restenosis.

Fourth-Generation Pipeline VantageFurther optimizations have been made, such as a thinner frame, higher porosity, and a novel micro-guidewire design.

Following the large-scale recall of Medtronic products this time, it may also further increase the market imagination space for the Tubridge product.